Uccc-Hn-19-01
Posted Date: Oct 26, 2020
- Investigator: Trisha Wise-Draper
- Specialties: Cancer, Head and Neck Cancer, Oncology
- Type of Study: Drug
The purpose of this study is to determine anti-tumor activity by measuring overall response rate in recurrent and/or metastatic HNSCC patients receiving the combination of metformin and pembrolizumab.
Criteria:
To Be Eligible: Must Have Histologically Or Cytologically Confirmed Recurrent Or Metastatic Non-Cutaneous Hnscc, Ecog 0-2, No Nasopharyngeal Hnscc, No Chemo Or Rt Within 2 Weeks, No Previous Treatment With Pd-1 Or Pd-L1 Inhibitors, No Metformin In The Past 6 Months
Keywords:
Head And Neck Cancer
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com